March 26, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics ... progression at month 12 compared to baseline in an ATTR-CM population with a high proportion of advanced heart failure ...
Payers may also be focusing more on big health challenges at the population level ... a range of inflammatory and autoimmune diseases, Intellia Therapeutics’ NTLA-2002 for hereditary angioedema ...
In October, CRISPR Therapeutics co-founder Emmanuelle Charpentier and Intellia co-founder Jennifer ... challenge will advance into the adult population of tomorrow. The ISPE Singapore Affiliate ...
Intellia Therapeutics, Inc. NTLA is developing its lead CRISPR-based, in vivo genome-editing candidate, nexiguran ziclumeran (nex-z, formerly known as NTLA-2001) for the treatment of transthyretin ...
ROME, March 31 (Reuters) - Italy's demographic crisis deepened in 2024 as the number of births hit a new record low, emigration accelerated and the population continued to shrink, national ...
We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Intellia Therapeutics, Inc. (NASDAQ:NTLA) stands against other best ...
Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for ...
In a highly unusual move, two seasoned sell-side biotech analysts at Cantor Fitzgerald are calling for the Trump administration to replace HHS Secretary Robert F. Kennedy, Jr., following the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback